All treatments
Treatment
Zirabev 25 mg/ml concentrate for solution for infusion. clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
Ezurpimtrostat autophagy inhibitor in association with Atezolizumab-Bevacizumab in first line treatment of unresectable hepatocellular carcinoma, a phase 2b randomized trial. ABE-LIVER
This study is testing a new drug, Ezurpimtrostat, alongside standard treatments (Atezolizumab and Bevacizumab) for advanced liver cancer that can't be removed by surgery. It aims to see how well this new combination stops the cancer from growing.
For: unresectable hepatocellular carcinomaFrance - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A global multicenter phase 1/2 trial of EO4010, a novel microbial-derived peptide therapeutic vaccine, in combination with nivolumab and/or bevacizumab, for treatment of patients with previously treated metastatic colorectal carcinoma (the "AUDREY" study).
This study, called "AUDREY," is for people with bowel cancer that has spread and has been treated before. It tests a new vaccine called EO4010 with existing cancer medicines to see if it's safe and helps improve treatment.
For: Patients with unresectable · previously treated locally advanced or metastatic colorectal carcinoma.France · Spain